Bax, bcl-2 and their homologues regulate a distal step in an evolutionary v
ery well conserved pathway of apoptotic cell death. It plays a crucial role
in the balance between proliferation rate and cell viability. Thus in the
last pars the attention of the scientific community towards these proteins
has remarkably increased, in particular in the oncologic field. We develope
d an immunohistochemical assay allowing us to evaluate the bax expression i
n formalin fixed and paraffin embedded lung cancer tissues to investigate b
ax expression in a cohort of 55 patients affected by non-small cell lung ca
ncer. We detected high expression of bax in 72.7% of our patients. When we
statistically analyzed our data we did not find any correlation between bar
expression and any clinicopathologic parameters (sex, age, TNM status tumo
r grade, histological type). In conclusion, our study shows the frequent ov
erexpression of bax, and this highlights the "apoptotic tendency" of cells
during the neoplastic proliferation. But, the role of bar in non-small cell
lung cancer pathogenesis still remains unclear and further studies of larg
e numbers of patients, including different stage groups, are needed to bett
er define the involvement of this protein in the complex mechanism of lung
carcinogenesis.